نتائج البحث

1

دورية أكاديمية

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

المؤلفون: Gelderblom, H., Gietema, J.A., Desar, I.M.E., Ajmone, N.M., Jalving, M., Kroep, J.R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S.F., Damstrup, L.

المصدر: Annals of Oncology ; volume 31, page S501-S502 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.715Test
https://api.elsevier.com/content/article/PII:S0923753420407112?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420407112?httpAccept=text/plainTest

View record in BASE

2

دورية أكاديمية

First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

المؤلفون: Gelderblom, H., Gietema, J. A., Desar, I. M. E., Ajmone, N. M., Jalving, M., Kroep, J. R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S. F., Damstrup, L.

المصدر: Gelderblom , H , Gietema , J A , Desar , I M E , Ajmone , N M , Jalving , M , Kroep , J R , Nicolas , V , Vaslin , A , Tobal , K , Purcea , D , van Haren , S F & Damstrup , L 2020 , ' First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours ' , Annals of Oncology , vol. 31 , pp. S501-S502 . https://doi.org/10.1016/j.annonc.2020.08.715Test

العلاقة: https://research.rug.nl/en/publications/1b92c166-6f8c-49d7-b4d1-5548c239e24eTest

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.715Test
https://hdl.handle.net/11370/1b92c166-6f8c-49d7-b4d1-5548c239e24eTest
https://research.rug.nl/en/publications/1b92c166-6f8c-49d7-b4d1-5548c239e24eTest

View record in BASE

3

دورية أكاديمية

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

المصدر: Jovanovic, J V; Ivey, A; Vannucchi, A M; Lippert, E; Oppliger Leibundgut, Elisabeth; Cassinat, B; Pallisgaard, N; Maroc, N; Hermouet, S; Nickless, G; Guglielmelli, P; van der Reijden, B A; Jansen, J H; Alpermann, T; Schnittger, S; Bench, A; Tobal, K; Wilkins, B; Cuthill, K; McLornan, D; . (2013). Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 27(10), pp. 2032-2039. Nature Publishing Group 10.1038/leu.2013.219

مصطلحات موضوعية: 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/47316Test/

الإتاحة: https://doi.org/10.1038/leu.2013.219Test
https://boris.unibe.ch/47316/1/28_JovanovicLeukemia2013.pdfTest
https://boris.unibe.ch/47316Test/

View record in BASE

4

دورية أكاديمية

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms:a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

المصدر: Jovanovic , J V , Ivey , A , Vannucchi , A M , Lippert , E , Oppliger Leibundgut , E , Cassinat , B , Pallisgaard , N , Maroc , N , Hermouet , S , Nickless , G , Guglielmelli , P , Van Der Reijden , B A , Jansen , J H , Alpermann , T , Schnittger , S , Bench , A , Tobal , K , Wilkins , B , Cuthill , K , McLornan , D , Yeoman , K , Akiki , S , Bryon , J , ....

مصطلحات موضوعية: JAK2-V617F, qPCR standardization, MRD, STEM-CELL TRANSPLANTATION, ACUTE LYMPHOBLASTIC-LEUKEMIA, DONOR-LYMPHOCYTE INFUSION, JAK2V617F ALLELE BURDEN, TYROSINE KINASE JAK2, POLYCYTHEMIA-VERA, ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS, MYELOID METAPLASIA, PEGYLATED INTERFERON-ALPHA-2A